cyrilzakka/clinical-trials huggingface dataset:
Effect of Short Foot Exercise in Treatment of Patients With Patellofemoral Pain Syndrome

Purposes of the study

To investigate the effect of adding Short foot exercise on patellofemoral pain syndrome on knee Pain, Function, Balance and abductors, quadriceps Muscle strength.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed as PFPS
* Pain elicited at least by two of the following four tests; (i) Isometric muscle contraction with slight bent knee,(ii) palpation of the patellofemoral joint line, (iii) patellar compression against the femoral bone (iv) active resisted knee extension.
* Psychological and mentally stable
* No previous knee surgery, except for diagnostic arthroscopy.
* No current knee pathologies (e.g. osteoarthritis)
* Navicular drop test more than 10 mm which indicated pronated foot

Exclusion Criteria:

- Subjects will be excluded if they don't meet the inclusion criteria.
Study Evaluating the Effect of Food on the Bioavailability of PN400 Components

We will evaluate the effect of food on the bioavailability of the components of PN400


Eligibility Criteria:
Inclusion Criteria:

* Healthy male or non-pregnant female subjects between 18-55 years old as well as other standard inclusion criteria for a study of this nature.

Exclusion Criteria:

* Standard exclusion criteria for a study of this nature.
Renal Arteries Dysplastic Aneurysms: Anatomopathological and Genetic Study

Fibromuscular dysplasia (FMD) is localized structural defects in the arterial wall, whose innate or acquired character is still unknown. This segmental non atheromatous injury, leads to stenosis of the arteries of small and medium caliber. Renal arteries are the most commonly affected with 60-75% of total fibrodysplasia. Three histological subtypes have been described: intimal, medial and peri-medial. They are not mutually exclusive and can be observed in the same patient.

This is a rare blood disease, occurring in children and young adults. In this young population with long life expectancy, these aneurysmal lesion are associated with 10% risk of rupture. To date, no data have shown in the literature that FMD is link to genetic causes, or if there is specific histopathologic lesions for non-atherosclerotic renal artery aneurysms.

To answer these questions, Cardiovascular Surgery Unit of the University Hospital of Saint-Etienne, French national reference center for renal artery surgery, in association with the Reference Center for Rare Vascular Disease in Paris, designed the first study for pathological and genetic characteristics of dysplastic renal artery aneurysms in young patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients with one or more Renal artery aneurysm (RAA), not eligible for endovascular treatment, have been operated at the Hospital of Saint-Etienne, with tissue (adjacent part and aneurysm) cryopreserved in liquid nitrogen in renal lab and then sent in genetic lab in Georges Pompidou European Hospital (EHGP ).
* Patient (or parent/person having parental authority) Affiliate or entitled to a social security scheme.
* Signature of patient consent (or parents or holder of parental authority)

Exclusion Criteria:

* Patient not included in the tissue collection in Georges Pompidou European Hospital (EHGP ).
* Patient refusing to participate in the study and / or genetic analysis or, for juvenile patients, parents or holder of parental authority refusing the minor patient to be involved in the study and / or genetic analysis.
* Patient with FMD whose samples in the tissue collection did not concern aneurysm.
Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole

Compare the DHE pharmacokinetic profiles observed following administration of:

1. MAP0004 (oral inhalation DHE)
2. MAP0004 co-administered with oral Ketoconazole
3. Intravenous (IV) DHE (D.H.E.45®, the approved reference therapy)

Compare the tolerability of MAP0004, IV DHE, and MAP0004 with co-administration of Ketoconazole.


Eligibility Criteria:
Major Inclusion Criteria:

* Able to provide written Informed Consent
* Male or Female subjects 18 to 45 years old
* Female subjects who are practicing adequate contraception or who are sterile
* Stable cardiac status
* Normal rhythm or arrhythmia deemed clinically insignificant on ECG

Exclusion Criteria:

* Contraindication to dihydroergotamine mesylate (DHE)
* Use of any excluded concomitant medications within the 10 days prior to Visit 1
* History of hemiplegic or basilar migraine
* Participation in another investigational trial during the 12 weeks prior to Visit 1 or during this trial
Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients

Primary sclerotic cholangitis (PSC) is an inflammatory process of sclerotic cholangitis that involves intra and extra hepatic biliary system. There is no curative treatment for this disorder. Supportive and conservative treatments are the most common therapies that used for this disease. Although treatments such as ursodeoxycholic acid (UDCA) are recommended in some situations but whereas a hypothesis is stimulatory effect of intestinal anaerobic bacteria such as cholestridium difficile as pathogenesıs of PSC, so use of antibiotics is recommended for treatment of these patients. Therefore according to the great role of anaerobic bacteria such as cholestridium difficile in pathogenesis, antibiotics such as metronidazole and vancomycin can be counted as recommended therapies in PSC. In addition some studies correlated this effect of vancomycin to its immunomudulatory effect the cause reduction of inflammation in biliary system. But with all this detail there is no finality about effectiveness of antibiotic therapy and accordingly in this study the investigators compare oral vancomycin effect versus placebo in primary sclerosing cholangitis patients.

In this double blind clinical trial 30 primary sclerosing cholangitis patients that divided in two 15 persosns group with Block Randomization method. in this study one group receive 250 mg oral vancomycin every 6 hours and other group receive placebo.

The study duration is 12 weeks . The baseline laboratory tests and 1 month and 3 months after treatment concept of; Alkaline phosphatase, ALT, AST, GGT and serum total bilirubin and clinical manifestations such as tiredness, itching and probable adverse effects such as hypotension accompanied by flushing,erythematous rash on face and upper body (red neck or red man syndrome), chills and drug fever, eosinophilia and reversible neutropenia.


Eligibility Criteria:
Inclusion Criteria:

1. primary sclerosing chollangitis diagnosis more than 3 months
2. inflammatory bowel disease with cholestasis diagnosis more than 3 months
3. confirmed RCPM
4. confirmed pathology of inflammatory bowel disease

Exclusion Criteria:

1. signs of uncompensated cirrhosis like: hepatic encephalopathy, esophageal varices bleeding
2. gastrointestinal cancer or hepatic cancer
3. immunosuppressive agent using for hepatic problem (not vancomycine hypersensitivity)
High-resolution Multi-parametric Magnetic Resonance Imaging for Focal Epilepsy

Patients with focal epilepsy often have diagnostic difficulties as their culprit for seizures are difficult to be picked up using conventional imaging. The current study is to investigate the utility of advanced MRI sequences on detection of subtle lesions accountable for focal epilepsy.

Focal epilepsy refers to having seizures arising from a specific part of the brain. In these patients, workup in magnetic resonance imaging is often necessary as patients with structural lesions have a much higher rate of seizures, ranging from 10% to 26% at 1 year and from 29% to 48% at 5 years. However, there is also a subgroup of patients who has epilepsy not adequately controlled by anti-epileptics with unrevealing first MRI study, a dedicated MRI protocol may reveal positive lesion in 30-65% of the cases. In these patients, several tricks can be applied to increase the detection rate. First, the used of a high-resolution MRI on a high-field scanner could be helpful, which can be increased the sensitivity up to 90%. The use of 7T-MRI in further picking up subtle lesions in patients presenting with epilepsy has been investigated, further affirming the role of high resolution MRI imaging. Secondly, the use of dedicated sequences, such as T1-weighted inversion recovery sequences which allow better distinction of grey and white matter, could also reveal subtle lesions such as polymicrogyria or Type 1 focal cortical dysplasia.

This study is therefore aimed to apply the findings to the local settings, and specifically to investigate if T1-weighted inversion recovery sequences provides additional benefit in picking up more subtle lesions in patients who had an initial first negative MRI.

Eligibility Criteria:
Inclusion Criteria:

* Consecutive patients with drug-resistant focal epilepsy fulfilling the following criteria -

  1. Diagnosis of focal epilepsy with a probable site identified, as defined by concordant results from any TWO of the following:
* Clinical seminology compatible with focal epilepsy.
* Electroencephalography pointing towards a specific site for focal epilepsy.
* Positive ictal brain scintigraphy with SPECT-CT correlation. AND 2. Previous MRI (at least one study with protocol tailored for epilepsy) which did not reveal accountable focal lesion.

AND 3. Able to consent for MRI examination (if patient under age of 18, consent for MRI will be obtained from guardian). Patients will be provided information leaflets to read on, and written consent before taking part in this study and MRI examination.

Exclusion Criteria:

* Patients who are contraindicated to magnetic resonance imaging (such as due to underlying MRI incompatible metallic implants)
* Patients who cannot cooperate for MRI scanning.
* Patients show are unable to provide informed consent.
Marijuana for Cancer Pain

To find out if it is safe and effective to use smoked marijuana in combination with opioids to treat cancer pain. The study will evaluate whether smoked marijuana, when used with opioids, will have an effect on pain relief, and to see if marijuana reduces the side effects of opioids, which include nausea and/or vomiting.

To take part in this study, you must have ongoing cancer pain which is currently being treated with opioids. If you meet all the eligibility criteria you will be admitted to the General Clinical Research Center at San Francisco General Hospital for 9 days. The treatment consists of smoking one marijuana cigarette 3 times a day.

Eligibility Criteria:
INCLUSION CRITERIA

* Have ongoing cancer pain
* Be diagnosed with cancer and have at least a six month survival.
* Be on a stable dose of opioid medication for at least 2 weeks before enrollment.
* Have smoked marijuana on at least 6 occasions in their lifetime prior to enrollment.

EXCLUSION CRITERIA

You must not:

* Start chemotherapy, radiation or biphosphonates during the study, or have received any new intervention with any such agents within the past 4 weeks.
* Currently be using smoked tobacco products.
* Currently be in methadone treatment.
* Have smoked marijuana within 30 days of enrollment.
* Be diagnosed with diabetes mellitus.
* Have severe heart disease, uncontrolled hypertension, or lung disease.
* Currently be receiving treatment with corticosteroids.
* Be pregnant or breastfeeding.
Effect of Dietary Sodium and Potassium Citrate on Renal Mineral Handling

This study intends to characterize the affect of sodium and potassium citrate in the diet on renal function.


Eligibility Criteria:
Inclusion Criteria:

* age 18 - 70, approximately equal numbers of men and women
* studied by endoscopy with complete papillary mapping and grading
* stone formers

Exclusion Criteria:

* Patients with primary renal diseases or renal impairment (eGFR \< 90), or medical conditions such as diabetes, or systemic diseases or medications that alter calcium metabolism
* Patients with known bladder voiding problems
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

This trial is conducted in United States of America (USA). The aim of this trial is to examine the bioequivalence of Norditropin® versus Genotropin® in healthy adult volunteers.


Eligibility Criteria:
Inclusion Criteria:

* Body mass index (BMI) 18.0-27.0 kg/m\^2 (both inclusive)
* Considered generally healthy upon completion of medical history, physical examination, vital signs, screening laboratory results, and electrocardiogram (ECG), as judged by the Investigator (trial physician)

Exclusion Criteria:

* The receipt of any investigational medicinal product within 1 month prior to this trial
* Current or previous treatment with growth hormone or IGF-I (insulin-like growth factor-I)
* Female of childbearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) for the duration of the trial
* Known presence or history of malignancy
* Diabetes mellitus
* Use of pharmacologic doses of glucocorticoids
* Use of anabolic steroids
* History of drug or alcohol abuse
Plasma Neurofilament Light and Its Relationship With Omega-3 Status and Soccer Heading in Women Soccer Players

The purpose of this study is to (1) assess how a competitive season of purposeful gameplay soccer heading in collegiate women soccer players is related to a blood biomarker for sports-related brain injury, plasma neurofilament light (NF-L), and (2) examine how a player's omega-3 status is related to plasma NF-L concentration changes during and after a competitive season of gameplay soccer heading.


Eligibility Criteria:
Inclusion Criteria:

* At least 18 years of age.
* Active player on the university's current team roster for the upcoming competitive season.
* Is eligible to participate in games and is not redshirting.

Exclusion Criteria:

* Is recovering from a Physician diagnosed concussion.
* Is recovering from another injury prohibiting the study participant from participating in all sport-related activities.
Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia

GATLA 8-AML´07 trial is an multicenter phase III dose-optimization trial for the treatment of acute myeloid leukemias in children and adolescents. Patients are treated with a combination of intensive chemotherapy in combination with intrathecal-injection by CNS and haematopoietic stem cell transplantation.

The patients are stratified in a standard-group (SR) and a high risk-group (HR). SR was defined as FAB (French-American-British) M1/M2 with Auer rods; FAB M4eo or favorable cytogenetics \[t(8;21)/AML1-ETO or inv(16) or t(16;16) and/or CBFB/MYH11)\]; bone marrow blasts ≤5% on day 15. HR was defined as all others. SR patients were reclassified to the HR group if FLT3-ITD positive.

Based on the experience of the BFM group, it was decided to randomly evaluate whether the six-drug conventional consolidation stage can be replaced with the use of a consolidation based by block therapy on drugs of proven efficacy in AML with the aim of reducing residual disease, and the toxicity of this stage. Patients are randomized once the double induction is completed into those who will receive the conventional consolidation phase and those who will receive consolidation with the combination of high doses cytarabine and two different anthracyclines sequentially.

All patients in the trial, whether standard risk (SR) or high risk (HR), receive 2 Induction courses: AIE and HAM and then are randomized to continue with the consolidation phase: a conventional consolidation (Arm A) with 6 drugs vs 2 blocks of chemotherapy that are incorporated in this protocol (AI and haM) (Arm B) and then an Intensification phase with high doses of cytarabine and etoposide. The difference between the SR and AR groups is that the former don't continue with the maintenance phase, while those in HR receive 1 year of Maintenance if they don't have a histoidentical family donor. SR patients according to cytogenetics and with \< 5% blasts in the bone marrow on day 15, haven´t indication for TCHP in 1st CR. HR patients, with a histoidentical family donor, will be transplanted in the 1st. CR after the Consolidation phases or the AI and haM blocks, according to the treatment arm that corresponded to them by randomization

Eligibility Criteria:
Inclusion Criteria:

* De novo AML
* FAB M0-M7
* Primary myelosarcomas or acute mixed lineage leukemia / biphenotypic leukemia (predominantly myeloid).
* Written informed consent from patients, parents, or guardians was obtained at study entry in accordance with the Declaration of Helsinki

Exclusion Criteria:

* AML as secondary malignancy
* Children with Down's syndrome
* Accompanying diseases which do not allow therapy according to the protocol
* Pre-treatment for more than 14 days with another intensive induction therapy
* Patients with APL
* Patients with myelodysplasia
* Patients with blast crisis of Chronic Myeloid Leukemia
* Patients who die before starting treatment
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.


Eligibility Criteria:
Inclusion Criteria:

* Participant had documented diagnosis of MDS according to World Health Organization (WHO) classification that met Revised International Prognostic Scoring System (IPSS-R) classification of very low-, low-, or intermediate-risk disease.
* Participant has an Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2.
* Participant must have red blood cell transfusions according to study criteria.

Exclusion Criteria:

* Participant has known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding.
* Participant has had a prior allogeneic or autologous stem cell transplant.
* Participant has known history or diagnosis of AML.
* Participant has uncontrolled hypertension.

Other protocol-defined inclusion/exclusion criteria apply
Analysis of the Biomechanics of Walking

The proportion of people aged 60 and over in the French population has increased from 18% in 1970 to over 22% in 2010.

One major problem in the elderly is falling. About half of these falls cause a minor injury and between 5% and 25% will cause a more serious injury such as a fracture or a sprain (Alexander et al., 1992; Nevitt et al., 1991).

It therefore seems essential to study the locomotion of seniors to limit the maximum risk of falling into a public health measure.

Two factors may be involved:

1. The first corresponds to factors related to natural aging topics
2. The second is the environment that is a real problem for seniors (Rolling showers, presence of works ....) And especially the port of inappropriate footwear.

Indeed, most of the elderly, institutionalized or not, do not wear proper shoes. It is this parameter that will be highlighted in our study.

The subjects will test different characteristics on the same shoe. A single parameter vary for each condition (Different insole, heel height, stem length ...) For each condition, analysis of locomotion on treadmill ADAL be performed as well as tests on postural balance platform. Kinematic measurements, accelerometer and postural will be performed for each subject.

Eligibility Criteria:
Inclusion Criteria:

* Topic of footwear for women 37-38-39 and 41-42-43 for men

Exclusion Criteria:

* Presence major pathology, fracture or surgery, at the musculoskeletal system, under 3 years
* Presence of prosthesis in the lower limb (hip, knee, ankle)
* Presence of hallux valgus or pronounced toe claw,
* Diabetes,
* Presence of osteoarthritis in the lower limbs
* Presence of medication or other problems affecting the balance of subjects.
Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients

This study, which was designed as a prospective observational study, was planned to enroll 75 female patients with postmenopausal osteoporosis who had been using bisphosphonates for more than two years and did not respond to treatment. 2 doses of denosumab were administered to the patients every 6 months. Bone mineral density of patients were measured with DEXA at the beginning and end of the study. A total of 66 patients completed the study.

At the end of the study, there was a significant improvement in the femur and lumbar total bone mineral density of the patients compared to the baseline. However, no statistically significant difference was found in terms of the frequency of new fractures.


Eligibility Criteria:
Inclusion Criteria:

* Being a woman with postmenopausal osteoporosis
* Being between the ages of 45-85
* Using bisphosphonate therapy for at least two years
* Vertebral and/or Femur T score below -2.5
* Unresponsive to bisphosphonate therapy

  * More than 2% decrease in BMD values despite using bisphosphonates and/or
  * New major fracture development during treatment

Exclusion Criteria:

* Male gender
* Being extremely thin (BMI \<15) or extremely obese (BMI\> 45)
* Malignancy
* Severe chronic liver and kidney failure
* Chronic Steroid use
* Having an active rheumatic disease
* Having other secondary causes of osteoporosis (primary hyperparathyroidism etc.).
Carotid Artery Corrected Flow Time as a Predictor of Hypotension After Induction of General Anesthesia in Elderly Patients

The number of elderly patients undergoing elective surgery has been growing in recent years. Elderly patients often have a variety of underlying diseases, including hypertension, coronary heart disease, diabetes, arteriosclerosis, etc., which increase the risk. When the elderly receive general anesthesia, hypotension often occurs after anesthesia induction. Once hypotension occurs, it may lead to myocardial ischemia, myocardial infarction, stroke and other serious complications. Therefore, in clinical anesthesia, a simple, quick and accurate prediction method is needed to evaluate and predict the risk of hypotension in elderly patients after induction, so that appropriate intervention measures can be taken in advance to reduce the incidence of hypotension in elderly patients after induction, thus reducing the occurrence of related complications and ensuring the safety of anesthesia and surgery.Carotid Artery Corrected Flow Time（FTc） is a recently developed volumetric predictor, which refers to the time between the the onset of systolic flow until the closure of the aortic valve. It is related to cardiac preload and can reflect cardiac output to a certain extent. It is considered as a reliable indicator for evaluating volume status and volumetric reactivity. Therefore, this study assessed the effect of FTc combined with perioperative fluid therapy on preventing hypotension after general anesthesia induction in elderly patients.


Eligibility Criteria:
Inclusion Criteria:

* patients who received elective surgery under general anesthesia, aged 65-85 years old, gender unlimited, ASAI-II

Exclusion Criteria:

* uncontrolled hypertension
* unstable angina pectoris
* history of myocardial infarction
* after heart stent implantation
* severe arrhythmia：Atrial fibrillation、Ventricular premature beat, frequent atrial premature beat, other non-sinus rhythm
* pacemaker implants
* cardiomyopathy
* a left ventricular ejection fraction of \< 40%
* history of neck trauma and surgery
* BMI\>30